Shares of Incyte stock opened at $60.60 on Friday. The company has a 50-day simple moving average of $69.53 and a two-hundred day simple moving average of $70.04. Incyte has a 52-week low of $50. ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Males also do a sexy shimmy to dazzle the ladies. Measuring no bigger than 0.2 inches (0.5 centimeters), the sparklemuffin peacock spider is, arguably, one of the cutest spiders around.

A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ruxolitinib cream 1.5% in adults with prurigo nodularis (PN). The data ...

Apr 14, 2023 1:48pm ET SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Incyte Corporation - INCY by Newsfile ...